ANZCTR search results

Iron deficiency anaemia is a common problem in pregnancy. It is often treated with high dose iron that cause constipation, stomach cramp and inhibit zinc absorption. Despite these concerns, there are no studies designed to work out the best dose of iron to treat anaemia in pregnancy. The aim of the study is to determine the dose that is most effective for the treatment of anaemia with least side effects. Three doses of iron (20mg/d, 40mg/d and 80mg/d) will be tested, and haemoglobin response and gastrointestinal side-effects will be assessed as the primary outcome. All researchers involved in the data collection and data analysis were blinded to the group allocation of the subjects until the primary analysis was completed.

This project aims to determine the best preventive methods for ECC by assessing variations of strategies. The strategies that will be used are • Education classes to antenatal and new parent groups • Preventive agents – participants will be randomly assigned to the following groups: toothbrushing with low-dose fluoride toothpaste, toothbrushing with 0.2 percent chlorhexidine gel, and toothbrushing with casein-phosphoprotein gel (CPP-ACP, Tooth Mousse) • Support through home visits and phone calls The effectiveness of these strategies will be assessed through • Pre and post questionnaires including dental knowledge, feeding practices and oral hygiene practices • Microbial analysis for the presence of decay-causing bacteria (blinded) • Dental screen analysis of participants having home visits (calibrated operators, not blinded) • Dental screen analysis at the 2 year recall (blinded) • Statistical analysis of data for case and control groups Participants will be recruited either from antenatal classes, pre-registration for maternity ward or new parent classes. All participants will be recalled when their child is approximately 6-9 months, 9-12 months and 15-18 months either through the home visit or by telephone. All will be asked to attend an appointment at the 24-26 month recall with their child. Swab samples of the teeth and gums will be taken and tested for the presence of decay-causing bacteria (mutans streptococci) and general oral bacteria in which participants will be informed of the results. The Mother’s teeth will be wiped with sterile cotton-tipped swabs at the initial contact, when the child is born and at the final recall. Those who wish to participate in home visits will also have their teeth swabbed at the 6-9 month period and their child’s teeth will be swabbed when their child is 6-9 months, 9-12 months and 15-18 months. Resources such as toothbrushes and preventive products will be supplied free of charge for the duration of participation or until the child is 24-26 months.

To discover if the consumption of foods made from CSIRO barley leads to changes in the levels of substances in the plasma (such as cholesterol) that would suggest they are beneficial for heart health.

The purpose of this stage of the study is to find out how well the livers of patients who have undergone chemotherapy and/or a liver resection regenerate after surgery compared to the livers of patients who have not undergone chemotherapy treatment. We are conducting this study because post-surgery assessment of liver function and the prediction of how well the liver functions after surgery in patients who have undergone chemotherapy and/or liver resection has not been examined. We will find this information out by conducting a liver function test using Indocyanine Green Clearance dye (ICG). This test provides us with an indication of how well your liver is functioning at a point in time.

The aim of this study is to evaluate whether Oxytocin facilitates extinction of conditioned fear. On day 1, participants 2 pictures are conditioned to the shock such that upon presentation of these pictures, participants respond with a fear response as indicated by skin conductance and expectancy measures. One picture is never paired with shock is a referred to as the safe cue. The next day (day 2) participants receive either OT or Placebo and return 45 minutes later. All three pictures are presented in the same way, except one of the pictures that was paird with shock originally is no longer paird with shock. This is called an extinction procedure. Participants then return the following day and are presented with the three pictures. We are assessing their fear response to the pictures with the hypothesis being that those who had the Oxytocin will respond with less of a fear response to the extinguished cue, as measured by skin conductance and expectancy measures, in comparison to those who received the placebo.

This study tests whether d-cycloserine improves the effectiveness of exposure therapy for decreasing social anxiety symptoms. We predict that individuals from the community diagnosed with social phobia who receive four exposure therapy sessions in comdination with D-Cycloserine will experience a greater reduction in social anxiety symptoms than individuals who receive placebo in combination with four exposure therapy sessions. Participants receive five weekly group therapy sessions. the first session is educational and the next four consist of public speaking exposure therapy. One month post intervention participants are assessed for social anxiety symptoms as well as other general health indicators. All subjects, therapists, assessors and data entry research staff are blind to condition.

The aim of this study is to evaluate the effectiveness of adding D-Cycloserine to group-based exposure therapy for panic disorder. It is hypothesised that individuals who receive D-Cycloserine and exposure therapy will attain a greater reduction in panic symptoms in comparison to individuals who receive placebo and exposure therapy. Participants from the community who have a primary diagnosis of panic disorder will receive three group based exposure therapy sessions in combination with placebo or D-Cycloserine. Exposure therapy consists of exposure to feared body sensations. Panic symptoms are assess one and three months later. All therapsists, assessors, and individuals entering data are blind to drug condition.

Patients with relapsed or resistant lymphoma require initial salvage chemotherapy to control their disease. One type of salvage chemotherapy is called ICE which can be given over 3 consecutive days as an outpatient for 3 cycles. On the day following each cycle of the ICE therapy (day 4) a single injection under the skin of pegfilgrastim is given to prevent the white blood cell count from falling too low. Provided patients respond to the salvage ICE chemotherapy, they then require high-dose chemotherapy as an inpatient. However, since this high dose therapy also kills some of the healthy white blood cells, it is necessary to collect stem cells from the blood before the high dose therapy. This is done by a process called leukapheresis. This study aims to collect stem cells by giving two doses of Pegfilgrastim on a single day, instead of 8-12 daily injections of standard filgrastim, following cycle 2 or 3 of ICE chemotherapy.

The objective of this study is to evaluate the long-term safety and tolerability of MP03-33, a nasal spray,over a 1-year period in patients with chronic allergic or nonallergic rhinitis. Commercially available azelastine hydrochloride nasal spray will serve as an active control.

The study is being conducted to prove/disprove the hypothesis that Sentinel Lymphadenectomy plus 5 years of serial nodal ultrasound is as effective as Sentinel Lymphadenectomy plus Complete Lymphadenectomy in prolonging disease free survival in patients with metastasis to the sentinel node. This trial is unblinded.